Mohammed Turab, Yu James, Qiao Yong, Kim Youngchul, Mortensen Eric, Swede Helen, Wu Zhao, Zhang Jingsong
Department of Hematology-Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Department of Statistics, University of Connecticut, Storrs, CT 06269, USA.
Biomedicines. 2024 May 3;12(5):1008. doi: 10.3390/biomedicines12051008.
Preclinical evidence indicates the potential anti-tumor capabilities of cannabinoids in prostate cancer (PC). We undertook a cross-sectional study using National Survey on Drug Use and Health data from 2002 to 2020, involving 2503 participants in the USA. The independent variable was marijuana use status (current, former, never), while the dependent variable was self-reported PC (yes, no). Eleven other demographic variables were assessed as covariates. PC prevalence was lower among current marijuana users (46/145, 31.7%) and former users (323/1021, 31.6%) compared to non-users (534/1337, 39.9%, < 0.001). PC prevalence was lower among users versus non-users in the elderly (≥65) (36.4% vs. 42.4%, = 0.016) and non-Hispanic white subgroups (28.9% vs. 38.3%, < 0.001). There were no significant PC prevalence differences between users and non-users in the younger population (50-64) or other race/ethnicity. In the multivariable analyses, former marijuana use was associated with lower PC compared to never using (odd ratio = 0.74, 95% CI 0.62-0.90, = 0.001). Current use was also suggestive of reduced prevalence but was not statistically significant (odd ratio = 0.77, 95% CI 0.52-1.14, = 0.198), possibly due to low sample size. Our findings from a large national survey provide additional data to link marijuana use with lower PC prevalence.
临床前证据表明大麻素在前列腺癌（PC）中具有潜在的抗肿瘤能力。我们利用2002年至2020年美国药物使用和健康全国调查数据进行了一项横断面研究，涉及美国2503名参与者。自变量是大麻使用状况（当前使用者、既往使用者、从未使用者），因变量是自我报告的前列腺癌（是、否）。另外11个人口统计学变量被评估为协变量。与非使用者（534/1337，39.9%，<0.001）相比，当前大麻使用者（46/145，31.7%）和既往使用者（323/1021，31.6%）的前列腺癌患病率较低。在老年人（≥65岁）（36.4%对42.4%，P = 0.016）和非西班牙裔白人亚组（28.9%对38.3%，<0.001）中，使用者的前列腺癌患病率低于非使用者。在年轻人群（50 - 64岁）或其他种族/族裔中，使用者和非使用者之间的前列腺癌患病率没有显著差异。在多变量分析中，与从未使用大麻相比，既往使用大麻与较低的前列腺癌患病率相关（比值比 = 0.74，95%置信区间0.62 - 0.90，P = 0.001）。当前使用也提示患病率降低，但无统计学意义（比值比 = 0.77，95%置信区间0.52 - 1.14，P = 0.198），可能是由于样本量较小。我们从一项大型全国性调查中得出的结果为大麻使用与较低的前列腺癌患病率之间的联系提供了更多数据。
